FDA Clearance Tracker · P120005-S067
Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring System
Last checked: Nov 20, 2026Latest source record: May 7, 2018 (this decision)Source: openFDAMethods & limitations
Decided
May 7, 2018
Approved
Time to decision
209 days
Received Oct 10, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P120005-S067
- Device name
- Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring System
- Applicant
- Dexcom, Inc.
- Applicant location
- San Diego, CA
- Received
- Oct 10, 2017
- Decided
- May 7, 2018
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P120005
Device type
- Device type
- Sensor, glucose, invasive (MDS)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the addition of a Manufacturing Site for components of the G4 Platinum and G5 Mobile Continuous Glucose Monitoring Systems at your facility located at 232 South Dobson Rd., Mesa, Arizona.
Source documents
Other decisions for Dexcom, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262472 · Decided Aug 11, 2026 · 25 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.